Leap Therapeutics Inc Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Leap Therapeutics Inc (NASDAQ: LPTX) today and set a price target of $12.50. The company’s shares closed yesterday at $7.49.

Ramakanth noted:

“Olga Smolentseva, Ph.D. – (646-975-6966) / osmolentseva@hcwresearch.com Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3).”

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.4% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.

Leap Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.

The company has a one-year high of $10.25 and a one-year low of $4.90. Currently, Leap Therapeutics Inc has an average volume of 126.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics. The firm’s pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.